Instituto Biomedico de Investigacion AC
Aguascalientes 20127
0 studies enrolling now · 12 studies all time
What they study most
Alzheimer Disease, B-cell Chronic Lymphocytic Leukemia, B-cell Lymphoma, Cardiovascular Disease, Epilepsies, Partial, Euvolemic Hyponatremia, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Partial Seizures, Refractory Partial Seizures, Relapsing Multiple Sclerosis
Studies at this site
- A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis — Completed
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
- A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — Completed
- A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy — Completed
- Once-A-Day Pregabalin For Partial Seizures — Completed
- Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures — Completed
- The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
- The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
- A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma — Stopped early
- Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients — Stopped early
- Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia — Completed